Novo Nordisk tells workers to return to office, Bloomberg reports

Novo Nordisk (NVO) CEO Maziar Mike Doustdar is calling workers back to the office as the Ozempic maker struggles to catch up with Eli Lilly (LLY) in the obesity market, Bloomberg’s Naomi Kresge reports. Office-based employees will need to come in five days a week starting January 1, 2026. The move just says after Doustdar announced the drugmaker would reduce its workforce by 9,000 positions.